Symptom → Plant Sources
Water Hyssop (Bacopa monnieri) as a tool for helping with Memory
inferred from neuroprotective action
Objectives Study aims were to evaluate effects of Bacopa monnieri whole plant standardized dry extract on cognitive function and affect and its safety and tolerability in healthy elderly study participants. Design The study was a randomized, double-blind, placebo-controlled clinical trial with a placebo run-in of 6 weeks and a treatment period of 12 weeks. Setting/location Volunteers were recruited from the community to a clinic in Portland, Oregon by public notification. Subjects Fifty-four (54) participants, 65 or older (mean 73.5 years), without clinical signs of dementia, were recruited and randomized to Bacopa or placebo. Forty-eight (48) completed the study with 24 in each group. Interventions Standardized B. monnieri extract 300 mg/day or a similar placebo tablet orally for 12 weeks. Outcome measures The primary outcome variable was the delayed recall score from the Rey Auditory Verbal Learning Test (AVLT). Other cognitive measures were the Stroop Task assessing the ability to ignore irrelevant information, the Divided Attention Task (DAT), and the Wechsler Adult Intelligence Scale (WAIS) letter-digit test of immediate working memory. Affective measures were the State-Trait Anxiety Inventory, Center for Epidemiologic Studies Depression scale (CESD)-10 depression scale, and the Profile of Mood States. Vital signs were also monitored. Results Controlling for baseline cognitive deficit using the Blessed Orientation-Memory-Concentration test, Bacopa participants had enhanced AVLT delayed word recall memory scores relative to placebo. Stroop results were similarly significant, with the Bacopa group improving and the placebo group unchanged. CESD-10 depression scores, combined state plus trait anxiety scores, and heart rate decreased over time for the Bacopa group but increased for the placebo group. No effects were found on the DAT, WAIS digit task, mood, or blood pressure. The dose was well tolerated with few adverse events (Bacopa n = 9, placebo n = 10), primarily stomach upset. Conclusions This study provides further evidence that B. monnieri has potential for safely enhancing cognitive performance in the aging.
Rationale Extracts of Bacopa monniera have been reported to exert cognitive enhancing effects in animals. However, the effects on human cognition are inconclusive. Objective The current study examined the chronic effects of an extract of B. monniera (Keenmind) on cognitive function in healthy human subjects. Methods The study was a double-blind placebo-controlled independent-group design in which subjects were randomly allocated to one of two treatment conditions, B. monniera (300 mg) or placebo. Neuropsychological testing was conducted pre-(baseline) and at 5 and 12 weeks post drug administration. Results B. monniera significantly improved speed of visual information processing measured by the IT task, learning rate and memory consolidation measured by the AVLT (P Conclusions These findings suggest that B. monniera may improve higher order cognitive processes that are critically dependent on the input of information from our environment such as learning and memory.
3 sources supporting Water Hyssop for Memory. Includes scientific publications, books, monographs and traditional-use references.
Mechanistic basis
This use is associated with the plant's neuroprotective / cognition support action. Further evidence for that pharmacology:
Bacopa monnieri has been used for centuries in Ayurvedic medicine as a memory and learning enhancer, sedative and anti-epileptic. This review highlights the health benefits of Bacopa monnieri extracts, focusing on anti-cancer and neurodegenerative diseases, and the molecular mechanisms underlying its cognition-enhancing, neuroprotective and therapeutic effects, as well as its toxicity, safety and synergistic potential.
This meta-analysis of randomized controlled trials found that standardized Bacopa monnieri extract improved cognition, particularly speed of attention, supporting the neuroprotective and cognitive-enhancing use of brahmi.
A randomized, double-blind, placebo-controlled trial evaluated a standardized Bacopa monnieri whole-plant dry extract on cognitive function, affect, safety and tolerability in healthy elderly participants. Bacopa improved measures of cognitive performance (e.g. delayed word recall and Stroop task) and reduced anxiety and depression scores relative to placebo, with good tolerability, supporting its traditional use as a memory and learning enhancer.
This review projects the beneficial role of Bacopa monnieri and its bacosides in disorders affecting the brain including Alzheimer's, Parkinson's, stroke, epilepsy and depression, supporting its neuroprotective use.
Ethanolic Bacopa monnieri extract inhibited Tau aggregation, lowered reactive oxygen species and restored Nrf2 levels in Neuro2a cells, acting as an antioxidant and neuroprotective agent relevant to Alzheimer's disease.
This review summarises experimental evidence for the neuroprotective potential of Bacopa monnieri (brahmi) in Alzheimer's, epilepsy, Parkinson's, Huntington's disease and cerebral ischemia.
This review describes the neuroprotective properties of Brahmi (Bacopa monnieri) and its bioactive components against Alzheimer's disease, including reduction of reactive oxygen species, neuroinflammation and amyloid-beta aggregation.